Scientists uncover protein that could help failing hearts
· Medical Xpressedited by Sadie Harley, reviewed by Robert Egan
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Associate Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
Researchers have identified a key protein that may help failing hearts regain function, offering new insight into why some hearts recover while others do not. The discovery comes from studying patients treated with left ventricular assist devices, or LVADs, which are mechanical pumps that reduce strain on the heart and allow it to rest and recover.
While these devices can stabilize patients with advanced heart failure, only a subset experience meaningful recovery, and the biological reasons have remained unclear.
In a study in the Journal of the American Heart Association, cardiovascular molecular researcher Junco Warren of Virginia Tech and cardiologist Stavros Drakos of University of Utah Health found that a protein called PERM1 is fully restored in patients whose hearts recover after LVAD support. Patients who did not recover showed no such restoration.
The study brought together scientists at Virginia Tech's Fralin Biomedical Research Institute at VTC and clinical collaborators at the University of Utah Health, combining molecular research with patient-based cardiac care.
Heart failure affects more than 6 million people in the United States, and predicting recovery remains a major challenge in care.
"This is the first muscle-specific molecular signal linked to recovery in human heart failure," said Warren, an assistant professor at the Fralin Biomedical Research Institute and co-corresponding author. "We don't yet know whether PERM1 drives recovery or reflects it, but it gives us a clear window into the biology of how recovery happens."
The research team analyzed heart tissue from 19 patients, comparing samples collected before and after LVAD implantation. Patients were enrolled through the University of Utah cardiac transplant program, with tissue collected from the left ventricular apex during implantation and later during device removal or transplantation. Patients were categorized as responders or non-responders based on improvements in heart function.
Before treatment, PERM1 levels were reduced in all patients. After LVAD support, levels were restored to near-normal only in those whose hearts recovered, while remaining suppressed in non-responders.
"This study begins to explain why some patients recover heart function with LVAD support while others do not," said Drakos, professor of cardiology at the University of Utah Health and co-corresponding author. "Identifying the biological signals behind recovery is essential to improving outcomes for patients with advanced heart failure."
The findings showed a strong correlation between PERM1 levels and improved cardiac function. PERM1 regulates how heart cells produce and use energy, and recovery was associated with normalization of stress-related metabolic pathways.
Together, the results position PERM1 as both a potential biomarker and a target for future therapies.
"Current therapies help manage heart failure, but they do not repair the heart muscle itself," Warren said. "Our findings point to a pathway that directly targets cardiomyocytes—the heart muscle cells—and restores both energy production and contractile function, the two core deficits in heart failure."
Previous work from Warren's lab showed that increasing PERM1 improves heart function in experimental models. The approach has also been shown to prevent heart failure in preclinical studies and may support recovery in advanced disease, including in patients receiving mechanical heart support.
"Heart failure creates a vicious cycle where energy loss and reduced contraction reinforce each other," Warren said. "PERM1 appears to act at the center of that cycle."
While more research is needed to determine whether PERM1 directly causes recovery, the findings provide a step toward new treatment strategies.
To help advance these discoveries toward patient use, Warren and members of her research team have co-founded a company focused on developing PERM1-based gene therapies.
Publication details
Karthi Sreedevi et al, PERM1 Is Selectively Restored in Left Ventricular Assist Device–Mediated Myocardial Recovery in Heart Failure, Journal of the American Heart Association (2026). DOI: 10.1161/jaha.125.044558
Journal information: Journal of the American Heart Association
Key medical concepts
Heart FailureLeft Ventricular Assist DeviceBiomarkersGene Therapy
Clinical categories
Cardiology Provided by Virginia Tech Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Scientists uncover protein that could help failing hearts (2026, May 21) retrieved 21 May 2026 from https://medicalxpress.com/news/2026-05-scientists-uncover-protein-hearts.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.